Literature DB >> 18385419

Staging of chronic kidney disease: time for a course correction.

Carolyn Bauer1, Michal L Melamed, Thomas H Hostetter.   

Abstract

Awareness of chronic kidney disease (CKD) has increased in part because of the definitions and treatment guidelines set out by Kidney Disease Outcomes Quality Initiative (KDOQI); however, the staging system set forth by these guidelines has led to several problems and unforeseen consequences. Stages 1 and 2 CKD are difficult to determine using the standard Modification of Diet in Renal Disease (MDRD) estimation of GFR, and their clinical significance in the absence of other risk factors is unclear. Just because microalbuminuria in people without diabetes is a cardiovascular risk factor does not make it kidney disease. Most patients who receive a diagnosis of stage 3 CKD (GFR between 30 and 59 ml/min) are elderly people, and the vast majority of these patients will die before they reach ESRD. The staging system needs to be modified to reflect the severity and complications of CKD. It is suggested that stages 1 and 2 be eliminated and stages 3, 4, and 5, be simply termed moderate impairment, severe impairment, and kidney failure, respectively. In addition, age should be a modifying factor, especially in moderate kidney impairment. These changes would allow identification and treatment of clinically relevant disease and avoidance of what can seem exaggerated prevalence estimates.

Entities:  

Mesh:

Year:  2008        PMID: 18385419     DOI: 10.1681/ASN.2008010110

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  45 in total

1.  Population-based risk assessment of APOL1 on renal disease.

Authors:  David J Friedman; Julia Kozlitina; Giulio Genovese; Prachi Jog; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

2.  Combining GFR and albuminuria to classify CKD improves prediction of ESRD.

Authors:  Stein I Hallan; Eberhard Ritz; Stian Lydersen; Solfrid Romundstad; Kurt Kvenild; Stephan R Orth
Journal:  J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 10.121

Review 3.  Mass spectrometry in chronic kidney disease research.

Authors:  Michael L Merchant
Journal:  Adv Chronic Kidney Dis       Date:  2010-11       Impact factor: 3.620

Review 4.  Integrating albuminuria and GFR in the assessment of diabetic nephropathy.

Authors:  George Jerums; Sianna Panagiotopoulos; Erosha Premaratne; Richard J MacIsaac
Journal:  Nat Rev Nephrol       Date:  2009-07       Impact factor: 28.314

5.  Early assessment of chronic kidney dysfunction using contrast-enhanced ultrasound: a pilot study.

Authors:  Y Dong; W-P Wang; J Cao; P Fan; X Lin
Journal:  Br J Radiol       Date:  2014-07-25       Impact factor: 3.039

6.  Association between deteriorated renal function and long-term clinical outcomes after percutaneous coronary intervention.

Authors:  Manabu Ogita; Kenichi Sakakura; Tomohiro Nakamura; Hiroshi Funayama; Hiroshi Wada; Ryo Naito; Yoshitaka Sugawara; Norifumi Kubo; Junya Ako; Shin-ichi Momomura
Journal:  Heart Vessels       Date:  2011-08-06       Impact factor: 2.037

7.  Controversies in chronic kidney disease staging.

Authors:  Kevan R Polkinghorne
Journal:  Clin Biochem Rev       Date:  2011-05

8.  eGFR: is it ready for early identification of CKD?

Authors:  Michal L Melamed; Carolyn Bauer; Thomas H Hostetter
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 8.237

9.  Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors.

Authors:  Emilio D Poggio; Andrew D Rule; Roberto Tanchanco; Susana Arrigain; Robert S Butler; Titte Srinivas; Brian R Stephany; Kathryn H Meyer; Saul Nurko; Richard A Fatica; Daniel A Shoskes; Venkatesh Krishnamurthi; David A Goldfarb; Inderbir Gill; Martin J Schreiber
Journal:  Kidney Int       Date:  2009-02-11       Impact factor: 10.612

Review 10.  Renal dysfunction in chronic liver disease.

Authors:  Andy Slack; Andrew Yeoman; Julia Wendon
Journal:  Crit Care       Date:  2010-03-09       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.